- CureVac - Wikipedia
On 11 March 2020, it was reported that CureVac AG's CEO Daniel Menichella was no longer the company's CEO, having been replaced by the company founder Ingmar Hoerr
- Alexander Zehnder, MD, MBA - CEO at CureVac - LinkedIn
As CEO of CureVac, I lead a dynamic team at the forefront of mRNA technology, pushing the boundaries of science to create next-generation vaccines and treatments for a wide range of diseases
- Alexander Zehnder - CEO at CureVac | The Org
Alexander Zehnder, MD, MBA, currently serves as the Chief Executive Officer of CureVac since April 2023
- CureVac Management
Dr Alexander Zehnder, M D, MBA, is Chief Executive Officer at CureVac N V since April 01, 2023 and is its Managing Director since March 2023 and serves as its Member of Management Board since 2023
- Leadership Team - CureVac
He is currently the CEO of Petalion Therapeutics, a UK-based biotechnology company developing targeted dendrimer therapies in oncology as well as a Venture Partner at Medicxi, a leading European life sciences investment firm
- CureVac–Zehnder A: management, 202304– CEO before Sanofi + Roche . . .
CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes
- CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing
- CureVac appoints new CEO - bionity. com
CureVac N V announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr Franz Haas will step down as CEO, effective March 31, 2023 Dr Alexander Zehnder will succeed Dr Haas, joining from Sanofi on April 1, 2023
|